BMS stops Phase III study of Opdivo in NSCLC as DMC asessment showed the drug had met its endpoint of overall survival.

BMS announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced, squamous cell Non-Small Cell Lung Cancer (NSCLC) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data � which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer � with health authorities.